ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
3 announcements with these filters
Fredun Pharmaceuticals delivered explosive Q1 FY27 growth with standalone income rising 90.44% YoY to INR 228.25 cr and PAT up 94.63% to INR 13.17 cr.
Fredun delivered strong Q4 FY26 performance with 27% revenue growth and 56% PAT growth. Transitioning from contract manufacturing to high-margin consumer brands in pet care, mobility, and anti-aging segments.
Fredun Pharmaceuticals reported strong Q3 FY'26 results with 57% revenue growth and 96% PAT growth, driven by its 'new-age' brands in pet care, nutrition, and dermaceutics.